

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [3821]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
It was raised during scoping that vadadustat will be the only recommended hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for people with anaemia in dialysis-dependent chronic kidney disease (DD-CKD). Access to an oral option at home could reduce inequalities in access to care for people with DD-CKD, given the severity and multi-comorbid nature of the disease, which may limit their ability to access outpatient anaemia care required for erythropoiesis-stimulating agent administration.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
The committee will consider all potential equality issues during the appraisal process.
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Approved by Associate Director (name): ...Richard Diaz.....

Date: 31 Jan 2024